AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 262 min read$TEM

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

Original reporting
finance.yahoo.com
Published Oct 26, 2026, 12:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 1:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Happens To Tempus AI Stock If Its Cash Burn Continues? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TEMBearishMed
01

Why it matters

The disclosed cash gap and debt increase raise concerns about liquidity, likely prompting a sell‑off unless revenue growth accelerates.

02

Market read

The article provides fresh guidance and financing details that could affect Tempus AI's valuation and the broader AI‑diagnostics niche.

03

What to watch

Potential upside from the Personalis acquisition and strong diagnostic revenue growth may offset short‑term cash strain.

Relevance 7/10Novelty 8/10Timing: today

Background

Tempus AI discussed its cash burn, cash position, debt level, and a recent $460M convertible note raise while outlining revenue guidance for 2026.

Company-level read

Ticker impact

$TEMBearishHigh confidence
Context

Tempus AI disclosed a $273M cash burn over the last year, $816M cash on hand, and a $460M convertible note offering to fund debt repayment and operations.

Expected impact

likely pressure as the market prices in cash‑burn risk and debt servicing concerns

Evidence & confidence

Large cash deficit and new debt issuance signal financial strain; investors may sell on heightened risk.

Market effects

Sector

Biotech and AI‑driven diagnostics may face tighter financing conditions as investors scrutinize cash burn.

Regional

US biotech sector could see modest pullback amid heightened cash‑flow concerns.

Global

Limited to investors with exposure to Tempus AI and similar high‑growth, cash‑intensive firms.

Counterpoint

What could challenge this read

The convertible note at 0% interest could be seen as cheap financing, supporting a turnaround if revenue growth sustains.

Key entities

  • company
    Tempus AI

    AI‑driven diagnostics and data licensing firm.

  • company
    Personalis

    Target of a 100% stock acquisition by Tempus AI.

Read at source← All news

Related articles

OCT 26
$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

biospace.com3 min
OCT 24
$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

econotimes.com2 min
OCT 23
$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.

finance.yahoo.com2 min
OCT 23
$BMYMedAI 8/10

Pathos AI partners with Bristol Myers Squibb and Tempus AI to accelerate medical research

Pathos AI, Bristol Myers Squibb, and Tempus AI partnered to accelerate medical research using AI. Pathos AI will access Tempus AI's patient database for $55M, while Bristol Myers Squibb gains strategic access to the technology. Pathos AI raised $237M to develop its platform and advance drug pipelines, including JSKN016 and a breast cancer program with AstraZeneca.

marketscreener.com2 min